It's never too early to start thinking about the holiday shopping season. Photo by Claudio Schwarz on Unsplash

One of the biggest headaches of online shopping and package shipping is the potential for delivery issues, and Texas is among the worst places for them, according to a new study.

Online retailer Overnight Glasses determined that Texas is the No. 5 worst state for package delays, based on a nationwide analysis of internet searches regarding delayed or lost packages, statewide United States Postal Service (USPS) performances, and freight flows per capita.

The data showed Texas had the highest freight flow compared to the rest of the U.S., raking in $3.64 billion. But the state’s massive population is a major factor contributing to “logistical challenges,” as shown in Texas’ local USPS performance rates.

“The USPS performance rate in Texas at an average 65 percent, and issues with timely deliveries, as reflected in the search value of 85.0 gives the state a high position in the ranking,” the report said.

Given the vast number of packages being sent through Texas’ delivery infrastructure, it’s safe to say Santa's going to be working overtime to fulfill the online orders for Houston's biggest spenders over the holidays.

The absolute worst place in the U.S. for package delays was North Dakota, which ranked as the No. 1 worst state for package delays.

The study found residents frequently search delivery issue terms such as “package delayed” or “order not delivered,” which doesn’t bode well for a state with a population of just 783,000.

“In today’s world, where everyone expects quick deliveries, even small hiccups can lead to a lot of frustration,” an Overnight Glasses spokesperson said. “I think this study highlights a real need for companies to invest in better, more flexible logistics networks, especially in states where freight flow is high.”

The best state for getting your packages delivered in a timely manner was Hawaii, followed by Oklahoma, West Virginia, Maryland, and Mississippi.

The top 10 worst U.S. states for package delivery issues are:

  • No. 1 – North Dakota
  • No. 2 – Georgia
  • No. 3 – Illinois
  • No. 4 – New York
  • No. 5 – Texas
  • No. 6 – Wyoming
  • No. 7 – Washington
  • No. 8 – Virginia
  • No. 9 – Massachusetts
  • No. 10 – South Carolina

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”